SLC5A2 and metabolic dysfunction-associated steatotic liver disease: In this work, a meta-analysis of randomized controlled trials was conducted to evaluate the effect of SGLT2 inhibitors on type 2 diabetes mellitus (T2DM) with NAFLD.